| Objective:To compare the efficacy of lobectomy and segmentectomy in the treatment of stage IA non-small cell lung cancer,and to analyze the overall recurrence rate,systemic complications and 5-year survival rate of lobectomy and segmentectomy in the treatment of stage IA non-small cell lung cancer by Meta-analysis.Methods:Relevant literatures were obtained from Pubmed,Web of Science,EMBASE,The Cochrane Library,CNKI,CBM,VIP and Wanfang databases.Inclusion and exclusion criteria were identified to screen articles for further systematic review and meta-analysis.Data related to segmentectomy group and lobectomy group were directly extracted or indirectly calculated from the included studies.Results: The current meta-analysis included 30 studies involving 12227 patients published from the establishment of the database to 2022.Compared with lobectomy,segmentectomy had a significant benefit on 3-year OS in patients with NSCLC whose preoperative CT image was ≤2cm(OR=0.86,95%CI: 0.75-1.00;P=0.05),there was no significant difference in 5-year OS(OR= 0.91,95%CI:0.76-1.09,P=0.30 > 0.05)OR 10-year OS(OR=1.22,95%CI: 0.67-2.21,P=0.51 > 0.05)among these patients.In the study of progression-free survival,patients had 3-year PFS(OR = 0.87,95%CI: 0.67-1.13,P=0.30 > 0.05),5-year PFS(OR = 0.87,95%CI: 0.69-1.10,P=0.26 > 0.05),had no significant difference in PFS.In the subgroup analysis,there was no significant difference between the 3-and 5-year LCSS.Conclusion: Our findings suggest that lobectomy is not superior to segmentectomy for stage IA NSCLC ≤2cm in terms of both long-term survival and progression-free survival,and may be the recommended surgical option.However,further randomized controlled studies and longer period of retrospective analysis are still needed for 10-year long-term survival and solid component analysis. |
